BackCytoMed Therapeutics Overview

CytoMed Therapeutics Total Liabilities

Track CytoMed Therapeutics's total liabilities ($1.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$1.13M
↑ 50.72% YoYΔ $380693.00 vs prior year quarter

Peer average

Loading

CytoMed Therapeutics Total Liabilities History

Loading

CytoMed Therapeutics vs. peers: Total Liabilities Comparison

Loading

CytoMed Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytoMed Therapeutics (GDTC) FAQ

CytoMed Therapeutics posts a total liabilities of $1.1M as of December 2025. That compares with $750K in the prior-year period — up 50.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CytoMed Therapeutics's total liabilities was $750K. The latest reading is $1.1M — a 50.7% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of CytoMed Therapeutics's financial statement story. At $1.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GDTC's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CytoMed Therapeutics's other metric pages and overview cover the third.